Occurrence of senescence-escaping cells in doxorubicin-induced senescence is enhanced by PD0332991, a cyclin-dependent kinase 4/6 inhibitor, in colon cancer HCT116 cells.
PD0332991
cell cycle
cellular senescence
doxorubicin
senescence-escaping cells
Journal
Oncology letters
ISSN: 1792-1074
Titre abrégé: Oncol Lett
Pays: Greece
ID NLM: 101531236
Informations de publication
Date de publication:
Jan 2019
Jan 2019
Historique:
received:
19
04
2018
accepted:
15
10
2018
entrez:
19
1
2019
pubmed:
19
1
2019
medline:
19
1
2019
Statut:
ppublish
Résumé
Cancer treatment induces cellular senescence, and it is considered to be one of the factors that determines treatment outcome. Senescence can be efficiently induced in cultured cells by DNA-damaging drugs, including doxorubicin (DOX), cisplatin and etoposide. Cells in senescence cease proliferation; however, it has been demonstrated that colonies that are formed from cells escaping senescence appear in drug-induced senescence; however, the conditions influencing the emergence of such senescence-escaping cells (SECs) remain unclear. The present study aimed to investigate the relevance of the cell cycle phase and colony formation in the DOX-induced senescence of human colon cancer HCT116 cells. After release from serum starvation in the presence of DOX, cells synchronously progressed through the cell cycle and were arrested in the G
Identifiants
pubmed: 30655877
doi: 10.3892/ol.2018.9657
pii: OL-0-0-9657
pmc: PMC6312925
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1153-1159Références
Genes Dev. 1999 Jun 15;13(12):1501-12
pubmed: 10385618
Oncogene. 1999 Aug 26;18(34):4808-18
pubmed: 10490814
Biol Chem. 2000 Sep-Oct;381(9-10):827-38
pubmed: 11076015
J Natl Cancer Inst. 2000 Dec 20;92(24):1999-2008
pubmed: 11121462
Cancer Res. 2001 Jun 1;61(11):4301-5
pubmed: 11389048
J Biol Chem. 2002 Sep 20;277(38):35509-15
pubmed: 12101184
Curr Cancer Drug Targets. 2003 Apr;3(2):153-9
pubmed: 12678717
Mol Cancer Ther. 2004 Nov;3(11):1427-38
pubmed: 15542782
Cell. 2005 Feb 25;120(4):513-22
pubmed: 15734683
Int J Biochem Cell Biol. 2005 May;37(5):961-76
pubmed: 15743671
J Med Chem. 2005 Apr 7;48(7):2388-406
pubmed: 15801831
Nat Rev Cancer. 2006 Jun;6(6):472-6
pubmed: 16723993
Mech Ageing Dev. 2009 Jan-Feb;130(1-2):24-32
pubmed: 18538372
J Biol Chem. 2009 May 1;284(18):12153-64
pubmed: 19269967
BMC Genomics. 2009 Mar 30;10:137
pubmed: 19331659
J Natl Cancer Inst. 2010 Oct 20;102(20):1536-46
pubmed: 20858887
Cell Signal. 2011 Jul;23(7):1076-81
pubmed: 21144894
Nat Rev Drug Discov. 2012 Dec;11(12):892-4
pubmed: 23197022
J Clin Invest. 2013 Mar;123(3):966-72
pubmed: 23454759
Oncotarget. 2015 Apr 10;6(10):8226-43
pubmed: 25803170
Clin Cancer Res. 2016 Jan 15;22(2):405-14
pubmed: 26369631
Trends Cell Biol. 2016 Mar;26(3):215-226
pubmed: 26564316
Nat Rev Cancer. 2016 Jan;16(1):20-33
pubmed: 26678314
Cancer Treat Rev. 2016 Apr;45:129-38
pubmed: 27017286
Aging Cell. 2016 Dec;15(6):999-1017
pubmed: 27628712
J Hematol Oncol. 2017 Apr 24;10(1):97
pubmed: 28438180
Exp Cell Res. 1980 Apr;126(2):397-405
pubmed: 6153987
Proc Natl Acad Sci U S A. 1995 Sep 26;92(20):9363-7
pubmed: 7568133
Cancer Res. 1994 Aug 15;54(16):4355-61
pubmed: 7913875
J Biol Chem. 1997 Aug 29;272(35):21681-4
pubmed: 9268294